Amit Maity MD PhD
Hematologic Malignancies
Professor and Chair, Dept. of Radiation Oncology, University of Utah School of Medicine
Join to View Full Profile
1950 City of Hope DriveRoom 1570Salt Lake City, UT 84112
Phone+1 801-581-2396
Fax+1 801-585-2666
Dr. Maity is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Amit Maity is a radiation oncologist in Salt Lake City, UT and works for University of Utah and the Huntsman Cancer Hospital. He received his medical degree from Boston University School of Medicine, then completed residencies in Internal Medicine at Mount Sinai Hospital in New York City and in Radiation Oncology at Hospital of the University of Pennsylvania followed by a PhD from the University of Pennsylvania. He has been in practice in radiation oncology for 35 years. He specializes in hematologic malignancies and is an active translational researcher.
Education & Training
University of PennsylvaniaPhD, Pathology, 1992 - 1995
University of Pennsylvania Health SystemResidency, Radiation Oncology, 1988 - 1991
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1985 - 1988
Boston University School of MedicineClass of 1985
Certifications & Licensure
UT State Medical License 2022 - 2026
NJ State Medical License 1992 - 2023
PA State Medical License 1988 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study.Steven Joel Feigenberg, Francesca Costabile, Ceylan Tanes, Kyle Bittinger, Roderick O'Connor
Journal for Immunotherapy of Cancer. 2025-07-10 - 2 citationsBridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study.Nikhil Yegya-Raman, John P Plastaras, Christopher M Wright, Monica Chelius, Siqi Zhang
Blood Advances. 2025-07-08 - 3 citationsFLASH proton reirradiation, with or without hypofractionation, reduces chronic toxicity in the normal murine intestine, skin, and bone.Ioannis I Verginadis, Anastasia Velalopoulou, Michele M Kim, Kyle Kim, Ioannis Paraskevaidis
Radiotherapy and Oncology. 2025-04-01
Abstracts/Posters
- A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell TherapyAmit Maity, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma PatientsAmit Maity, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Proton Therapy Center Expansion Set to Dramatically Increase Patient Capacity Across the Mountain WestAugust 8th, 2025- Proton Therapy Center Expansion Will Significantly Boost Patient Capacity Across the Mountain WestAugust 8th, 2025
- Penn Scientists Aim to Bring Promising Cancer Therapy Closer to RealityMarch 2nd, 2022
- Join now to see all
Grant Support
- Combination of CB101 and radiation therapy in head and neck squamous cell carcinomaCUREBIOTECH, INC.2022–2025
- Regulation Of Vegf/Hif-1 By AKT: Implications For RadiotherapyNational Cancer Institute2006–2010
- Regulation Of VEGF In Tumors By RAS, EGF And PTENNational Cancer Institute2002–2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
